Rosen Law Firm Alerts AstraZeneca Investors on Class Action Deadline

NEW YORK, Feb. 09, 2025 (GLOBE NEWSWIRE) --

WHY: The Rosen Law Firm, a respected global investor rights law firm, is reminding investors who purchased securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022, and December 17, 2024 (the "Class Period"), of the important lead plaintiff deadline set for February 21, 2025. This deadline relates to a securities class action that the firm has initiated.

SO WHAT: If you bought AstraZeneca securities during the Class Period, you might qualify for compensation without the need to pay any upfront fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To become part of the AstraZeneca class action, you can submit your information at this link, or you can call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for more information on the class action. A lawsuit has already been filed, and if you wish to serve as the lead plaintiff, you must file your motion with the court by February 21, 2025. The lead plaintiff acts on behalf of other class members in managing the litigation.

WHY CHOOSE ROSEN LAW FIRM: It is essential for investors to select experienced legal counsel with a strong record of success in analogous leadership roles. Many firms sending out notices do not possess similar experience, resources, or recognition among their peers. Furthermore, several of these firms do not actively litigate securities class actions, instead acting merely as middlemen who refer clients to more capable law firms. Choosing seasoned counsel is crucial. The Rosen Law Firm represents investors worldwide, focusing on securities class actions and shareholder derivative litigation. The firm has also achieved notable results, including the largest securities class action settlement against a Chinese company at the time. Additionally, the Rosen Law Firm was recognized as the number one firm for securities class action settlements in 2017 by ISS Securities Class Action Services and has consistently ranked in the top four from 2013 onwards, recovering hundreds of millions of dollars for investors. In 2019, the firm recovered more than $438 million for its clients. The founding partner, Laurence Rosen, was named a Titan of the Plaintiffs' Bar by Law360 in 2020, with many attorneys at the firm having received recognition from Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, during the Class Period, defendants made materially false and misleading statements and failed to disclose critical information, including: (1) AstraZeneca involved in insurance fraud activities in China; (2) increased legal exposure in China resulting in the detainment of AstraZeneca's China President by local authorities; (3) underreporting of legal risks faced by AstraZeneca; (4) potential harm to AstraZeneca's business activities in China once the truth came to light; and (5) therefore, the defendants' claims about the company's business operations and outlook were materially misleading. Once investors learned the truth, they reportedly experienced damages.

To join the AstraZeneca class action, please visit this link, call Phillip Kim, Esq. toll-free at 866-767-3653, or email [email protected] for more information.

Note that no class has been certified, and until such a class is recognized, you are not represented by counsel unless you choose to retain one. You also have the option to remain an absent class member and take no action at this point. An investor's potential to benefit from any future recovery does not rely on serving as the lead plaintiff.

Follow updates from the Rosen Law Firm on LinkedIn, Twitter, or Facebook.

Attorney Advertising. Past results do not guarantee future similar outcomes.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40^th Floor
New York, NY 10016
Phone: (212) 686-1060
Toll-Free: (866) 767-3653
Fax: (212) 202-3827
Email: [email protected]
Website: www.rosenlegal.com

AstraZeneca, classaction, securities